Skills (61)
Research experience
-
Teaching: Chemistry Department
-
Teaching: University of Missouri-Kansas City. 1998-1999: Instructor of physical chemistry lab and Adjunct Lecturer in chemistry
-
Teaching: School of Biological Sciences
-
Teaching: 1996-1997: Graduate Teaching Assistant in Biology
-
Teaching: Spring 2009.
-
Teaching: CHEM446 and CHEM447
-
Teaching: lecturer and lab instructor for the biochemistry courses
-
Teaching: Spring - Fall 2008. Development
-
Teaching: CHEM248 and CHEM249 (Fall 2007
-
Teaching: lecturer and lab instructor for the analytical chemistry labs
-
Teaching: organic chemistry and advanced biochemistry and lab instructor of all chemistry labs for the same disciplines. Development
-
Teaching: inorganic
-
Teaching: Lehman College (CUNY). Lecturer in general chemistry
-
Teaching: Chemistry Department
-
Teaching: original contribution for development of an advanced biochemistry lab for BS students (CHEM 447). 2006 - Adjunct Assistant Professor in Chemistry
-
Teaching: advanced biochemistry (CHEM447) and lab Instructor of all chemistry labs for the same disciplines
-
Teaching: 234 and 235
-
Teaching: 233
-
Teaching: organic chemistry (CHEM232
-
Teaching: inorganic
-
Teaching: Lehman College (CUNY). Lecturer in general chemistry (CHEM 114 and CHEM 120
-
Teaching: Chemistry Department
-
Teaching: development of a new biochemistry lab. 2001-2006: Adjunct Lecturer in chemistry
-
Teaching: introductory organic (CHEM120) and biochemistry lab (CHEM347
-
Teaching: Hunter College (CUNY). Instructor of general chemistry (CHEM114
-
Teaching: Chemistry Department
-
Teaching: City College (CUNY). 200-2001: Adjunct Lecturer in chemistry
-
Aug 2007–
Jul 2012Research: collagen I and II processing by dendritic cells
Albert Einstein College of Medicine · Pathology · Albert Einstein College of MedicineLaura Santambrogio · Bronxplasma membrane and late endosomal antigen processing -
Aug 2007–
presentResearch: Albert Einstein College of Medicine
Albert Einstein College of Medicine · Department of PathologyUSA · New York City -
Jul 2007–
Jul 2012Research: proteomics and peptidomics of human lymph
Albert Einstein College of Medicine · Pathology · Albert Einstein College of MedicineLaura Santambrogio · Bronxmass spectroscopy and proteomics -
Nov 2005–
Aug 2007Research: Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center · Division of Molecular Pharmacology & ChemistryUSA · New York City -
Nov 2005–
Jul 2007Research: drug design and SAR for hsp-90 and Hsp-70
Sloan Kettering Institute · Chemistry/Molecular Pharmacology · Sloan Kettering InstituteGabriela Chiosis · NYC-Manhattanpharmacology -
Aug 2002–
Aug 2012Research: peptides inhibitors for thrombin
Lehman College-CUNY · Chemistry · Lehman College-CUNYManfred Philipp · Bronx, NYCdrug design and SAR peptides synthesis anti-thrombosis research -
Dec 2001–
Dec 2013Research: CUNY Graduate Center
City University of New York City - Lehman College · ChemistryUSA · New York City -
Aug 2001–
Dec 2013Teaching: Lehman College
Lehman CollegeUSA · Bronx -
Sep 1999–
May 2006Research: DNA translesion synthesis past bulky adducts
Hunter College · Chemistry · Hunter CollegeMaria Tomasz · Manhattan, NYCmitomycin adducted DNA templates polymerases and DNA translesion past mytomycin adducts
Education
-
Aug 1998–
May 2006Graduate Center-City University of New York
Biochemistry · Ph.D.United States of America (USA) · NYC -
Aug 1995–
Sep 1998Biological Sciences-University of Missouri Kansas City
Cell and Molecular Biology · Master Science (MS)United States of America (USA) · Kansas City
Other
-
LanguagesEnglish, French
-
Scientific Memberships2001 - Graduate student and associate member, American Chemical Society (ACS).
2002 - Graduate student and postdoctoral member, American Peptide Society (APS).
2004 - Associate Member, Sigma Xi Chemical Society, Chemistry Department, Lehman
College Chapter.
2004 - Associate Member, American Society for Biochemistry and Molecular Biology (ASBMB).
2008 - American Society for Cell Biology.
2009 - Member of American Society for Mass Spectroscopy (ASMS).
-
Journal RefereesCBDD (ChemBiology&Drug Design)
-
Other Interestshiking
traveling in different cities and visiting historical places
photography and film making, Science
Medicinal Chemistry
Chemical-Biology (ACS)
PlosOne
Nature
Biochemistry
Proteomics
, Jack London Martin Eden, The Sea-Wolf, The Call of the Wild, Mark Twain's Novels, Charles Dickensavid Copperfield, Great Expectations, Henry James Daisy Miller, The Turn of the Screw, If Poem, Rabindranath Tagore Gora, Oscar Wilde the Picture of Dorian Gray, Charlotte Brontë Jane Eyre, Tennessee Williams Cat on a Hot Tin Roof, The Glass Menagerie, A Streetcar Named Desire, Summer and Smoke, Albert Camus La Peste, Franz Kafka/The Trial, The Castleand 4 more
Publications (27) View all
-
Article: Age-related oxidative stress compromises endosomal proteostasis.
[show abstract] [hide abstract]
ABSTRACT: A hallmark of aging is an imbalance between production and clearance of reactive oxygen species and increased levels of oxidatively damaged biomolecules. Herein, we demonstrate that splenic and nodal antigen-presenting cells purified from aging mice accumulate oxidatively modified proteins with side-chain carbonylation, advanced glycation end products, and lipid peroxidation. Furthermore, we show that the endosomal accumulation of oxidatively modified proteins interferes with the efficient processing of exogenous antigens and degradation of macroautophagy-delivered proteins. In support of a causative role for oxidized products in the inefficient immune response, a decrease in oxidative stress improved the adaptive immune response to immunizing antigens. These findings underscore a previously unrecognized negative effect of age-dependent changes in cellular proteostasis on the immune response.Cell reports. 07/2012; 2(1):136-49. -
Article: Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
[show abstract] [hide abstract]
ABSTRACT: Triple-negative breast cancers (TNBCs) are defined by a lack of expression of estrogen, progesterone, and HER2 receptors. Because of the absence of identified targets and targeted therapies, and due to a heterogeneous molecular presentation, treatment guidelines for patients with TNBC include only conventional chemotherapy. Such treatment, while effective for some, leaves others with high rates of early relapse and is not curative for any patient with metastatic disease. Here, we demonstrate that these tumors are sensitive to the heat shock protein 90 (Hsp90) inhibitor PU-H71. Potent and durable anti-tumor effects in TNBC xenografts, including complete response and tumor regression, without toxicity to the host are achieved with this agent. Notably, TNBC tumors respond to retreatment with PU-H71 for several cycles extending for over 5 months without evidence of resistance or toxicity. Through a proteomics approach, we show that multiple oncoproteins involved in tumor proliferation, survival, and invasive potential are in complex with PU-H71-bound Hsp90 in TNBC. PU-H71 induces efficient and sustained downregulation and inactivation, both in vitro and in vivo, of these proteins. Among them, we identify downregulation of components of the Ras/Raf/MAPK pathway and G(2)-M phase to contribute to its anti-proliferative effect, degradation of activated Akt and Bcl-xL to induce apoptosis, and inhibition of activated NF-kappaB, Akt, ERK2, Tyk2, and PKC to reduce TNBC invasive potential. The results identify Hsp90 as a critical and multimodal target in this most difficult to treat breast cancer subtype and support the use of the Hsp90 inhibitor PU-H71 for clinical trials involving patients with TNBC.Proceedings of the National Academy of Sciences 06/2009; 106(20):8368-73. · 9.68 Impact Factor -
Article: Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.
[show abstract] [hide abstract]
ABSTRACT: Although androgen receptor (AR)-mediated signaling is central to prostate cancer, the ability to modulate AR signaling states is limited. Here we establish a chemical genomic approach for discovery and target prediction of modulators of cancer phenotypes, as exemplified by AR signaling. We first identify AR activation inhibitors, including a group of structurally related compounds comprising celastrol, gedunin, and derivatives. To develop an in silico approach for target pathway identification, we apply a gene expression-based analysis that classifies HSP90 inhibitors as having similar activity to celastrol and gedunin. Validating this prediction, we demonstrate that celastrol and gedunin inhibit HSP90 activity and HSP90 clients, including AR. Broadly, this work identifies new modes of HSP90 modulation through a gene expression-based strategy.Cancer Cell 11/2006; 10(4):321-30. · 26.57 Impact Factor -
Dataset: Dev Cell
-
Article: Protein Expression Profiles of Human Lymph and Plasma Mapped by 2D-DIGE and 1D SDS-PAGE Coupled with NanoLC-ESI-MS/MS Bottom-Up Proteomics.
[show abstract] [hide abstract]
ABSTRACT: In this study a proteomic approach was used to define the protein content of matched samples of afferent prenodal lymph and plasma derived from healthy volunteers. The analysis was performed using two analytical methodologies coupled with nanoliquid chromatography-tandem mass spectrometry (nanoLC Orbitrap-ESI-MS/MS) on a linear ion trap mass spectrometer: one-dimensional gel electrophoresis (1DEF nanoLC Orbitrap-ESI-MS/MS), and two-dimensional fluorescence difference-in-gel electrophoresis (2D-DIGE nanoLC-ESI-MS/MS). The 253 significantly identified proteins (p<0.05), obtained from the tandem mass spectrometry data, were further analyzed with pathway analysis (IPA) to define the functional signature of prenodal lymph and matched plasma. The 1DEF coupled with nanoLC/MS/MS revealed that the common proteome between the two biological fluids (144 out of 253 proteins) was dominated by complement activation and blood coagulation components, transporters and protease inhibitors. The enriched proteome of human lymph (72 proteins) consisted of products derived from the extracellular matrix, apoptosis and cellular catabolism. In contrast, the enriched proteome of human plasma (37 proteins) consisted of soluble molecules of the coagulation system and cell-cell signaling factors. The functional networks associated with both common and source-distinctive proteomes highlight the principal biological activity of these immunologically relevant body fluids.PROTEOMICS 11/2012; · 4.51 Impact Factor
About
1st job: Research-scientist in anti-cancer, anti-atherosclerosis/thrombosis and other pathological human conditions: molecular pathology based on molecular, cellular biochemistry and pharmacology.
2. 2nd job: Professor in Chemistry-Biochemistry.
